Clinical Trial Update: Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating the combination of duvelisib and venetoclax in relapsed or refractory peripheral T-cell lymphoma, with recruitment ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Prolymphocytic Leukemia

Drugs mentioned

• COPIKTRA (duvelisib)
• Venclexta (venetoclax)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory | Phase 1, Phase 2 | Status: RECRUITING